Ten years ago, our team published a commentary on what assuredly appeared to be the “Death of CNS Drug Development: Overstatement or Omen” after several large pharmaceutical companies abandoned or severely restricted neuropsychiatric drug development efforts citing costly and long development periods with relatively lower chances of successful drug applications. Christine K. Moore, Natalia E. Drosopoulou and Henry J. Riordan at Worldwide Clinical Trials talk about portending a renaissance in neuroscience drug development.